Mettrum Launches Research Program to Determine How Cannabis Strains Should Be Prescribed

TORONTO - Mettrum Health Corp. ("Mettrum" or the "Company") (TSXV:MT), a vertically integrated licensed producer (LP) of cannabis products, this week launched the Mettrum Registry Research Program (MRRP) to systematically gather data on up to six thousand Canadian patients who have been prescribed medical cannabis.

The goal of this observational study is to provide information to prescribing physicians and the wider medical community to help determine if and how cannabis should be prescribed – focusing on which strains best suit a particular patient's needs. It also considers the impact of intercurrent illness or potential interactions with other medications. The study will run for one year, with results anticipated to be published by March 2017.  

"Our motivation for conducting this research is to ensure that individuals who are prescribed Mettrum Dried Cannabis or Cannabis oils, are able to receive the full potential of their prescription," said Michael Haines, CEO of Mettrum. "We believe...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.